Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Return on Capital Employed of 20.34% for Q1 2026, up 39.58% on a QoQ basis from 14.57% in Q4 2025, and up 2400.0% year-over-year from 0.81% in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2010 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 20.34% for Q1 2026.
- Quarterly Return on Capital Employed rose 2400.0% year-over-year to 20.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.34% (up 2400.0% YoY) and the FY2025 annual result came in at 15.99%, up 2220.0% from the prior year.
- Return on Capital Employed was 20.34% for Q1 2026 at Alnylam Pharmaceuticals, up from 14.57% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.34% in Q1 2026 and bottomed at 31.68% in Q2 2023.
- A 5-year average of 10.07% and a median of 6.52% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 3526 bps — and 2025, when it tumbled 942 bps.
- Alnylam Pharmaceuticals' Return on Capital Employed stood at 28.31% in 2022, then soared by 65 bps to 9.84% in 2023, then jumped by 41 bps to 5.83% in 2024, then jumped by 350 bps to 14.57% in 2025, then soared by 40 bps to 20.34% in 2026.
- Business Quant data shows ALNY's Return on Capital Employed at 20.34% in Q1 2026, 14.57% in Q4 2025, and 8.39% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 20.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.34% |
| Dec 31, 2025 | 14.57% |
| Sep 30, 2025 | 8.39% |
| Jun 30, 2025 | -5.83% |
| Mar 31, 2025 | -3.66% |
| Dec 31, 2024 | -5.83% |
| Sep 30, 2024 | -6.52% |
| Jun 30, 2024 | 3.59% |
| Mar 31, 2024 | -6.09% |
| Dec 31, 2023 | -9.84% |
| Sep 30, 2023 | -13.27% |
| Jun 30, 2023 | -31.68% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -28.31% |
| Sep 30, 2022 | -29.74% |
| Jun 30, 2022 | -26.23% |
| Mar 31, 2022 | -22.82% |
| Dec 31, 2021 | -24.76% |
| Sep 30, 2021 | -24.59% |
| Jun 30, 2021 | -26.59% |